DDIF 2027 · The programme
12 May 2027 · 09:00
Delegates arrive. The room settles. Conversation begins before the programme does.
12 May 2027 · 10:00
Target identification. Lead optimisation. The decisions that determine whether a compound enters development.
12 May 2027 · 12:30
Curated seating. Facilitated by the chair. The conversations continue at the table.
12 May 2027 · 14:00
Process development. GMP readiness. The manufacturing decisions that determine whether a candidate becomes a medicine.
12 May 2027 · 16:30
Preclinical to IND. The regulatory strategy decisions made before a single patient is enrolled.
12 May 2027 · 19:00
By invitation. Closed. The conversation continues at the table.
13 May 2027 · 09:00
From Phase I to submission. Regulatory strategy. EMA and FDA navigation from a position of authority.
13 May 2027 · 11:00
AI and machine learning in drug discovery. Informatics platforms. The technology behind the compound.
13 May 2027 · 13:00
The room speaks. The chair closes. What compounds. What translates. Who reaches the patient.
13 May 2027 · 14:00
The room closes. The circle continues.
Compound. Translate. Approve.